Literature DB >> 12626443

Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults.

Uwe Schauer1, Frank Stemberg, Christian H L Rieger, Wolfgang Büttner, Michael Borte, Simone Schubert, Helga Möllers, Frank Riedel, Udo Herz, Harald Renz, Wilhelm Herzog.   

Abstract

Antibody levels specific for capsular polysaccharides of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) and for tetanus toxoid were measured in serum samples of 386 age-stratified subjects. The study group consists of healthy adult blood donors and hospitalized children undergoing elective surgery, excluding individuals with a history of infection. In children, anti-tetanus toxoid antibody levels displayed two peaks of 1.20 IU/ml (20.4 mg/liter) and 1.65 IU/ml (28.1 mg/liter) related to the schedule of routine childhood immunization in the first year and at 8 years of age. Eighty percent of the antibodies are of the immunoglobulin G1 (IgG1) isotype. For pneumococcal capsular polysaccharide (PCP), the specific antibody levels represent the acquisition of natural immunity. The initial concentration of 9.2 mg/liter was low in infancy (0.5 to 1 years of age) and remained low until 3 to 4 years of age (14.6 mg/liter). During this period PCP antibodies were almost 100% of the IgG2 subclass. Thereafter, IgG anti-PCP antibody titers increased steadily to adult levels (59.5 mg/liter). The data are intended to provide reference ranges to aid in the interpretation of specific antibody determinations in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626443      PMCID: PMC150524          DOI: 10.1128/cdli.10.2.202-207.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  35 in total

1.  Interlaboratory reproducibility of an enzyme-linked immunosorbent assay for quantitation of antibodies for Haemophilus influenzae type b polysaccharide.

Authors:  D V Madore; S A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 2.  Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies.

Authors: 
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

3.  Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs.

Authors:  A F Ochsenbein; D D Pinschewer; S Sierro; E Horvath; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

4.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

5.  Haemophilus influenzae type b and cross-reactive antigens in natural Hib infection dynamics; modelling in two populations.

Authors:  T Leino; K Auranen; P H Mäkelä; H Käyhty; M Ramsay; M Slack; A K Takala
Journal:  Epidemiol Infect       Date:  2002-08       Impact factor: 2.451

6.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

7.  Response to oligosaccharide-protein conjugate vaccine against Hemophilus influenzae b in two patients with IgG2 deficiency unresponsive to capsular polysaccharide vaccine.

Authors:  R A Insel; P W Anderson
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

8.  Immunoglobulin subclasses in normal children.

Authors:  P H Schur; F Rosen; M E Norman
Journal:  Pediatr Res       Date:  1979-03       Impact factor: 3.756

9.  Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants.

Authors:  R A Insel; P W Anderson
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  35 in total

1.  A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.

Authors:  Floriane Fusil; Sara Calattini; Fouzia Amirache; Jimmy Mancip; Caroline Costa; Justin B Robbins; Florian Douam; Dimitri Lavillette; Mansun Law; Thierry Defrance; Els Verhoeyen; François-Loïc Cosset
Journal:  Mol Ther       Date:  2015-08-18       Impact factor: 11.454

2.  Measurement of pneumococcal polysaccharide vaccine responses for immunodeficiency diagnostics: combined IgG responses compared to serotype specific IgG responses.

Authors:  Willemijn J M Janssen; Andries C Bloem; Perijne Vellekoop; Gertjan J Driessen; Marianne Boes; Joris M van Montfrans
Journal:  J Clin Immunol       Date:  2013-07-24       Impact factor: 8.317

3.  Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Authors:  Vijay G Bhoj; Dimitrios Arhontoulis; Gerald Wertheim; James Capobianchi; Colleen A Callahan; Christoph T Ellebrecht; Amrom E Obstfeld; Simon F Lacey; Jan J Melenhorst; Farzana Nazimuddin; Wei-Ting Hwang; Shannon L Maude; Mariusz A Wasik; Adam Bagg; Stephen Schuster; Michael D Feldman; David L Porter; Stephen A Grupp; Carl H June; Michael C Milone
Journal:  Blood       Date:  2016-05-10       Impact factor: 22.113

4.  Identification and characterization of the constituent human serum antibodies elicited by vaccination.

Authors:  Jason J Lavinder; Yariv Wine; Claudia Giesecke; Gregory C Ippolito; Andrew P Horton; Oana I Lungu; Kam Hon Hoi; Brandon J DeKosky; Ellen M Murrin; Megan M Wirth; Andrew D Ellington; Thomas Dörner; Edward M Marcotte; Daniel R Boutz; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

5.  Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.

Authors:  Dawn B Beaulieu; Ashwin N Ananthakrishnan; Christopher Martin; Russell D Cohen; Sunanda V Kane; Uma Mahadevan
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-01       Impact factor: 11.382

6.  Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements.

Authors:  Thomas M Daly; Jerry W Pickering; Xiaochun Zhang; Harry E Prince; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

7.  Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass.

Authors:  Stephan von Gunten; David F Smith; Richard D Cummings; Stefan Riedel; Sylvia Miescher; Alexander Schaub; Robert G Hamilton; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2009-05-13       Impact factor: 10.793

8.  [Adult-onset primary immunodeficiencies].

Authors:  S Gadola; U Salzer; H Schultz; B Grimbacher
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

9.  Reference ranges and cutoff levels of pneumococcal antibody global serum assays (IgG and IgG2) and specific antibodies in healthy children and adults.

Authors:  M A Rose; J Buess; Y Ventur; S Zielen; E Herrmann; J Schulze; R Schubert
Journal:  Med Microbiol Immunol       Date:  2013-03-26       Impact factor: 3.402

10.  Effect of Chronic Social Stress on Prenatal Transfer of Antitetanus Immunity in Captive Breeding Rhesus Macaques (Macaca mulatta).

Authors:  Rachelle L Stammen; Joyce K Cohen; Tracy L Meeker; Maria M Crane; Rama R Amara; Sakeenah L Hicks; Jerrold S Meyer; Kelly F Ethun
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-05-15       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.